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Acute Promyelocytic Leukemia as a Possible Source for Ajulemic Acid Binding 
Brian Christopher Monk 
Abstract 
Acute pro myelocytic leukemia (APL) is a cancer that affects bone marrow, 
the blood-forming tissue (of the body) . This type of leukemia accounts for 
approximately 10% of acute myeloid leukemia (AML) cases. Normally this cancer is 
treated with a drug called all-trans retinoic acid (ATRA), but other variations of 
treatment do exist. The importance of this research is that APL cells express 
contains a receptor, retinoic acid receptor-a (RARa), which ajulemic acid (AJA) may 
bind to in order to induce apoptosis in Ewing sarcoma (ES), a pediatric bone cancer. 
Therefore, this research will focus on the ability of AJA to induce the differentiation 
of APL cells, as ATRA does, thus demonstrating that AJA may be binding to RARa. 
Introduction 
Acute Promyelocytic Leukemia 
APL is a type of cancer that affects the bone marrow. Normally, bone marrow 
produces cells known as hematopoietic stem cells, which give rise to a variety of 
different cells within the body. Some of the cells produced include: red blood cells 
(erythrocytes), white blood cells (leukocytes), and cell fragments called platelets 
(thrombocytes) (Collins, 2002). However, in patients with APL, stem cells are not 
able to differentiate, or become specialized into mature functional white blood cells. 
Instead, immature white blood cells (WBC) accumulate within the bone marrow. 
This results in a shortage of a normal amount of erythrocytes, leukocytes, and 
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thrombocytes within the body. Figure 1 shows the pathway that a hematopoietic 
stem cell takes to reach one of its three outcomes: erythrocyte, leukocyte, or 
thrombocyte. 
Blood stem cell 
Myeloid stem cell 
\ 











White blood cells 
Figure 1: The image above shows the normal route of a hematopoietic stem 
cell takes to become a red blood cell (RBC), platelet, or WBC. 
From: The National Cancer Institute "What You Need to Know About 
Leukemia." 
In patients with APL, the problem arises in a cell called a 
promyelocyte. Promyelocytes are derived from myeloblasts and eventually give 
way to granulocytes. These then go on to produce neutrophils, eosinophils, 
basophils, and mast cells (Figure 2). In APL the promyelocytes are unable to 
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differentiate into these different types ofWBCs and cause blockage within the 
marrow, leading to the overall effect of fewer RBC, WBC, and platelets. 
Figure 2: Promyelocytes that differentiate into different WBC. (Left to right: 
neutrophil, monocyte, basophil, lymphocyte, and eosinophil). 
From: The University of California at San Francisco, Science & Health 
Education. 
APL accounts for approximately 10% of all acute myeloid leukemia (AML), 
and occurs in 1 out of every 250,000 people in the United States (Yamamoto, et al., 
2007). With that, it accounts for 21,700 deaths per year and has a higher incidence 
rate within the Hispanic community. The average APL patient is diagnosed around 
age 40, but can be diagnosed at any age. 
APL is caused by a translocation of two chromosomes: 15 and 17 (The, 
1991). Normally on chromosome 15, the PML gene, produces a protein that acts as 
a tumor suppressor (Salomoni, et al., 2002). This protein is able to prevent cells 
from growing and replicating too rapidly within the body. Chromosome 17, 
containing the RARa gene, produces a protein that helps regulate gene transcription 
(the first step in the formation of protein production) (The, et al., 1991). This 
protein controls genes in WBC differentiation beyond the promyelocye stage. With 
patients that have APL, 98% of the cases are due to the translocation, or fusion, of 
both chromosomes 15 and 17 (Zelent, et al., 2001). The fusion of these 
chromosomes produces a gene called PML-RARa. This gene interferes with both the 
normal processes of chromosomes 15 and 17. It does so by producing cells that are 
caught in the promyeloctye stage, leading to abnormal differentiation and 
accumulation. Ultimately this does not allow for the formation of mature and 
functional WBC. Interestingly enough, APL is not a genetic disease (Zelent, et al., 
2001). It is acquired throughout one's lifetime and is only present in certain cells. 
This specific type of mutation is called a somatic mutation. 
Diagnosis of this disease is done through observation of signs and symptoms, 
as well as diagnostic procedures. Normal symptoms that are observed in patients 
with APL are: fatigue, weakness, anemia (low RBC), bruising, bleeding, fever, and 
infection (Sanz, et al., 2010). In a proper diagnosis, a doctor would note all signs and 
symptoms of the patients, and order certain tests. These test check the patient's 
complete blood count (CBC), electrolyte levels, prothrombin time (PT) (blood test to 
measure how long it requires blood to clot), and activated partial thromboplastin 
time (aPPT) (blood test that characterizes blood coagulation). In addition, a bone 
marrow biopsy would be done to test for the presence of abnormal WBC. 
There are many different treatment options for patients with APL; the 
normal treatment being all-trans-retinoic acid (ATRA) in combination with a 
chemotherapeutic anthracycline drug (daunorubicin or idarubicin) (Attar, et al., 
2013). ATRA helps promyelocytes differentiate into functioning neutrophils, 
reduces the total number of leukemic cells within the bone marrow, and aids in 
reducing the side effects of chemotherapy. For patients who cannot handle the use 
of anthracycline drugs or who relapse, ATRA with arsenic trioxide (As03) is 
prescribed (Gore, et al., 2010). Overall, 80% of patients achieve short-term 
remission when treated with ATRA alone and 70-80% achieve remission when 
treated with the combination of both ATRA and an anthracycline (The Leukemia and 
Lymphoma Society.). Those who achieve remission must undergo long-term follow-
ups to ensure they are cured of the disease and determine if additional therapy is 
required. Therapy in order to maintain remission consists of treatment with 6-
mercaptopurine (6-MP), methotrexate, and ATRA for at least two years (Gore, 
2010). 
Ewing's Sarcoma 
Ewing's sarcoma (ES) is a cancer that occurs in either bones or soft tissues. 
There are several different types of ES, each affecting a different part of the body 
(Bailly, et al., 1994). Besides ES of the bone, there is extra osseous ES, which are 
tumors that occur in the soft tissues that surround the bone (i.e. cartilage). 
Peripheral primitive neuroectodermal tumors (pPNET) occur within nerve tissues. 
Askin tumors, a subtype of pPNET, are located within the chest. 
Out of all these different types of ES, 87% occur in the bones. Figure 3 shows 
the areas of the body that are affected (Sankar, eta!., 2011). Common cases ofES 
occur in the femur (thigh), pelvis, or humorous (arm). Abnormal cases would 
consist of ES affecting the ribs, spine, etc. It is very common that ES will metastasize 
to another part of the body. Lungs, other bones, or marrow, are typical places to see 
the cancer spread. 
ES affects approximately 3 out of 1 million children each year (Sankar, eta!., 
2011). In the United States, 250,000 are diagnosed with some form of ES each year, 
making it the second most common form of bone cancer. ES tends to affect children 
and young adults who are between the ages of 10 and 20. Affecting more boys than 
girls, and rarely occurring in either African-Americans or Asian Americans, ES 
accounts for 1.5% of all pediatric cancers that are diagnosed. 
Like APL, Ewing's sarcoma is not inherited genetically, making it a somatic 
mutation. ES arises from the translocation of two genes EWSR1 on chromosome 22 
and FLil on chromosome 11 (May, 1993). When parts of these two genes fuse 
together, they create the EWSR1/FLI1 gene. This gene is what leads to the 
development of ES. Normally, the FLI1 protein helps regulate transcription as well 
as binding to DNA (May, 1993). The protein then helps control the overall 
development of certain cells by controlling the rate of transcription of certain genes. 
Regulating transcription is also the major function of the EWSR1 protein, under 
normal conditions (Mao, et al., 1994). However, when the two genes fuse together, 
the new protein turns transcription on or off on a variety of different genes, 
ultimately leading to abnormal differentiation and growth of cells. In patients 
diagnosed with ES, 85% of them have the ESWR1/FLI1 mutation. 
Diagnosis of this cancer is done through both observations of signs and 
symptoms, as well as diagnostic procedures. Normal signs and symptoms that are 
apparent in patients withES are: edema (swelling) or soreness around the area of 
the tumor, a low-grade fever, bone pain that specifically intensifies during exercise 
or while sleeping, and limping caused by the tumor being present on the bone (St. 
Jude). Using diagnostic procedures, a physician would use not only a physical exam, 
but also an MRI, CT, bone scan, bone marrow biopsy, or the use of PCR for the 
EWSR1/FLI1 gene, to help make a definitive diagnosis of ES. Typical treatment for 
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ES includes chemotherapy, surgery (possibly amputation to guarantee that all the 
cancer is removed) and radiation (St. Jude). The overall survival rate for children 
withES is 70%, however that number drastically decreases to 30% for 5-year 
survival rate. 
Figure 3: Image depicting occurrences of Ewing's Sarcoma (ES) within the 
body. 
From: Dr. Frank Gaillard, et a!. 
Cannabinoids 
Cannabinoids have been used for recreational purposes for sometime now. 
However, these recreational drugs are being studied for their potency on cancer. 
Research defines a cannabinoid by its ability to bind to either CB1 or CBz (Figure 4). 
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The CB1 receptor is found throughout the body in places such as the brain, spleen, 
eye, testis, and uterus (Cridge, et al., 2013). CBz on the other hand, is found on cells 
that deal with the immune system as well as tumor cells. These receptors belong to 
a specific type of protein receptors called G-protein coupled receptors, whose 
purpose is to transduct signals from outside the cell. The CB1 receptor mediates 
psychotropic effects of cannanibinoids (Cridge, et al., 2013). On the opposite side, 
CBz functions in moderating the immune system's effect (Cridge, et al., 2013). 
X 
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Figure 4: Image shows the two cannabinoid receptors (CB1 and CBz) and 
their physical shapes. 
From: pubs.rsc.org 
Research showing that cannabinoids do in fact inhibit tumor growth is 
extensive. A specific cannabinoid-.18- THC (tetrahydrocannabinol)-was used on mice 
with lung cancer. Researchers found that after twenty days of treatment, the drug 
inhibited growth of the tumor. Ceramides were found to be very prominent when 
either CB1 or CBz were activated (Cridge, et al., 2013). Ceramides are very 
important in physiological signaling, controling events such as apoptosis (cell 
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death), growth arrest (certain stage within the cell cycle), differentiation of cells, cell 
migration and adhesion. When either CB1 or CBz were activated, researchers saw an 
increase in ceramide levels, which led to apoptosis or cell cycle arrest within tumor 
cells. Cannabinoids were found to prevent angiogensis (the formation of new blood 
vessels). This is a critical necessity for tumors in order to develop and when 
undergoing treatment with cannabinoids, researchers found decreased angiogenic 
activity (Cridge, et al., 2013) . 
Although there are many derivatives of cannabinoids that are undergoing 
further studies to test for efficacy on cancer, our research focused on ajulemic acid 
(AJA). AJA (CzsH3604), shown in Figure 5, is a crystalline solid at room temperature 
and has shown to inhibit psychotropic effects when administered (Burstein, 2004). 
This makes it a very good treatment for Ewing's sarcoma because children won't 
experience the high that is associated with normal cannabis plants. The drug has 
shown to bind effectively to both the cannibinoid receptors (Burstein, et al., 2013). 
<·uun 
Figure 5: Ajulemic Acid (AJA) (CzsH3604, MW= 400.55 gjmol) shows 
excellent capabilities in the treatment of cancers, especially Ewing's sarcoma. 
From: Sumner Burstein"Ajulemic Acid {IP-751): Synthesis, Proof of Principle, 
Toxicity Studies, and Clinical Trials", 2004 
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Relevance of Study 
The purpose of this study is to test a possible receptor to which AJA may be 
binding. Previous research has indicated that AJA binds to a certain receptor called 
peroxisome proliferator-activated receptor gamma (PPAR-y) (Liu, 2003). When ES 
cells were tested in the lab for the expression ofthis receptor via Western blot, 
PPAR-y was not expressed. Therefore, it was concluded that AJA was binding to 
another receptor. Studies done from previous research found possible candidates 
for A} A's binding site. The RARa and vitamin D receptors were among some of the 
strongest candidates. This particular research was to focus on the RARa receptor. 
By using APL cells, which not only express the RARa receptor, but ligand-binding to 
this receptor can be easily monitored by assessing the differentiation of APL cells. 
This experimental model was perfect to see if AJA binds to RARa. 
Several other drugs were tested alongside AJA. ATRA was used as a positive 
control in order to compare the efficacy of the two drugs. Other drugs, 9 cis-retinoic 
acid ( cis-RA), cannabidiol (CBD), and hemp oil, were used to test the efficacy on APL. 
Hemp oil and CBD were used to test other derivatives from the cannabis plant. 
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Materials 
Ajulemic Acid (A]A) 
AJA, dimethylheptyl-THC-11-oic acid, was prepared in dimethyl sulfoxide 
(DMSO) to a final stock concentration of 10 mM. 
All-Trans Retinoic Acid (ATRA) 
ATRA, was prepared in ethanol to a final stock concentration of0.01 mM and 
1mM. 
9 Cis-Retinoic Acid (cis-RAJ 
Cis-RA, was prepared in DMSO to a final stock concentration of 0.1 mM. 
Hemp Oil 
Hemp oil, was prepared in DMSO to a final stock concentration of 0.1 mM and 
l!JM. 
Cannabidiol (CBD) 
CBD, was prepared in ethanol to a final stock concentration of 0.1 mM and 1 
mM. 
Cell Culture 
HL-60 cells (leukemic cells from an APL patient) were grown in suspension 
in IMDM media (20% fetal bovine serum (FBS) with penicillin and streptomycin) 
and cultured at 37°C with 5% COz. 
11 
Methods 
Maintenance of Cell Line 
Cells were maintained to produce enough viable cells in order to test the 
efficacy of different treatment options. One of the main indicators of cell line 
maintenance was a foggy, milky color being present. If present, this allowed us to 
properly spilt the HL-60 cells (place old cells into a new flask with fresh media and 
providing new media for the original flask as well). This process was repeated 
throughout the experiment. Another indicator we used was a microscope. When 
viewing the cells, if there were a lot of dead cells in the flask, this was an indicator 
that they too needed to be split. 
NBTAssay 
The efficacy of treatment of AJA on APL cells was done via NBT (nitro blue 
tetrazolium) assay composed of two tetrazole moieties (5-membered ring with 4 
nitrogen's and 1 carbon). The NBT assay procedure was prepared by first spinning 
down cells in the centrifuge and vacuuming off media. Cells were suspended in 1 
mL of NBT /PMA (composition of solution) that was warmed before submersion of 
cells. Cells were then placed into the incubator for 30 minutes at 37°C. After the 30 
minutes, 83 ~L of HCl was added to the cells. The addition of HCl stops the reaction 
of the NBT /PMA with APL cells. Cells were then spun down and liquid was 
vacuumed off. Cells were then suspended in 0.5 mL of DMSO; which caused a purple 
color to form. The cells plus DMSO were moved to a well plate in order to be read 
by the TECAN Infinite Series at 560 nm. The machine measured absorbency by 
measuring the light that was absorbed. The effectiveness of treatment is indicated 
17 
by the shade of purple produced from the assay. Thus the darker the shade of color, 
the more effective and vice versa. Results were drafted and saved. 
The NBT assay tests for oxidative free radicals produced by WBCs. In 
patients who do not suffer from APL, pathogens that are recognized are targeted 
with oxidative radicals produced from the WBCs. In patients with APL, this process 
does not occur. Thus, the darker shade of purple produced from the assay tells us 
that AJA caused the cells to differentiate into normal WBCs. The lighter the color, 
the less effective the drug was on APL cells. 
The NBT assay was performed with all drugs used to test for the 
differentiation of APL cells. 
Results 
APL Treatment with ATRA 
To establish a positive control, we first tested ATRA on APL cells. ATRA is 
the normal treatment for APL; therefore we would have a positive baseline for AJA 
when it underwent testing. HL-60 cells were grown and cultured, in order to get a 
sufficient amount to treat. Cells were either untreated (UT) or treated with ATRA 
(30 nM). The amount of cells needed for treatment was calculated and found to be 
1x104 cellsjmL. The average amount of cells in each flask (2 UT and 2 ATRA) were 
calculated via hemocytometer. The following results were obtained: 
Average Number of Average Number of 
Untreated APL Cell for UT ATRA APL Cells Cells for A TRA 
Cells (cellsjmL) (cellsjmL) 
A 272x104 A 159x104 
B 198.5x104 B 207.5x104 
1~ 
Following total cell count of the both UT and ATRA cells, NBT assay was 
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Figure 6: Results showing the absorbance of 560nm for UT APL cells and 
ATRA treated APL cells. 
APL Treatment with ATRA & A]A 
Having established a positive control for the experiment, comparing ATRA vs. 
AJA was next. Cell lines from the previous experiment were continuously grown 
and cultured. Cells were divided into three categories of treatment: UT, ATRA (30 
nM), or AJA (30 nM). The amount of cells needed for treatment was calculated and 
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found to be 1x107 cells/mL. The average number of cells was calculated via 
hemocytometer. The following results were obtained. 
Average Average 
Average Number of Number of 
Untreated Number of ATRAAPL Cells for AJAAPL Cells for 
APL Cells Cells for UT Cells ATRA Cells AJA 
(cells/mL) (cells/mL) (cells/mL) 
A 313.5x104 A 303x104 A 221.5x104 
B 303x104 B 201x104 B 207x104 
Following total cell count for UT, ATRA, and AJA, NBT assay was performed 


































Untreated 30nM AJA 30nM ATRA 
Figure 7: Results showing differentiation between APL UT, AJA, and ATRA 
(**p-value<.OS). 
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APL Treatment with ATRA and Varying Concentrations of A]A 
Evaluating the results shown in Figure 7, we decided to vary the 
concentration of AJA, to see if a higher molar concentration induced differentiation. 
Using the stock concentration of AJA we calculated the different molar 
concentrations (M1V1=MzVz). Cell lines were continuously grown and cultured. 
Upon treatment, cells were divided into five categories: UT, ATRA (30 nM), AJA (30 
nM), AJA (300 nM), and AJA (3 11M). The amount of cells needed for treatment was 
calculated and found to be 1x107 cells/mL. The average number of cells was 
calculated via hemocytometer. The following results were obtained. 
Average Average AJA Average AJA Average AJA Average 
Number ATRA Number APL Number APL Number APL Number 
Untreated of Cells APL of Cells Cells of Cells Cells of Cells Cells of Cells 
APL Cells forUT Cells for ATRA (30 for APL (300 for APL (3 for APL (3 
(cellsjmL) (cells/mL) nM) (30 nM) nM) (300 nM) !lM) !lM) 
(cells/mL) (cells/mL) (cells/mL) 
A 237x104 A 233x104 A 212x104 A 244x104 A 237x104 
B 196xl04 B 214x104 B 207xl04 B 241x104 B 213x104 
Following total cell count for UT, ATRA, AJA (30 nM), AJA (300 nM), and AJA 
AJA (3 11M), NBT assay was performed on all five trials. Figure 8 shows the results 
obtained from the experiment. 
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Figure 8: Results showing the differentiation between APL UT, ATRA, AJA 
(30 nM), AJA (300 nM), and AJA AJA (311M). 
APL Treatment with ATRA, A]A, CBD, and Hemp Oil 
The final experiment was to test different cannabinoids on the differentiation 
of APL cells. Cells were continuously grown and cultured before the experiment. 
Using the stock concentrations of the different drugs, we calculated the different 
molar concentrations (M1 V1=MzVz). Upon treatment, cells were divided into nine 
catagories: UT, ATRA (30 nM), cis-RA (30 nM), AJA (30 nM), AJA (311M), CBD (30 
nM), CBD (3 11M), Hemp oil (30 nM), and Hemp oil (3 11M). The total number of cells 
needed for treatment was calculated and found to be 1x107 cellsjmL. The average 
number of cells was calculated via hemocytometer. The following results were 
obtained. 
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Average Average Cis-RAAPL Average AJAAPL Average 
Number of ATRAAPL Number of Cells (30 Number of Cells (30 Number of 
Untreated Cells for UT Cells Cells for nM) Cells for cis- nM) Cells for AJA 
APL Cells (cellsjmL) ATRA RA (30 nM) (30 nM) 
(cellsjmL) ( cellsjmL) (cellsjmL) 
A 4x107 A 4.5x107 A 4.3x107 A 3.2x107 
B 4.7x107 B 4 Sx107 B 4.3x107 B 3.6x107 
Average Average Average Average Average 
AJAAPL Number of CBDAPL Number of CBD APL Number of Hemp Oil Number of Hemp Oil Number of 
Cells (3 Cells for Cells(30 Cells for Cells(3 APL Cells APL Cells Cells for APL Cells Cells for 
1-!M) AJA(3 nM) CBD (30 1-!M) for CBD (3 (30 nM) Hemp Oil (31-!M) Hemp Oil 
1-!M) nM) 1-!M) (30 nM) (31-!M) 
(cells/mL) (cells.mL) (cells/mL) (cells/mL) (cells/mL) 
A 3.2x107 A 3.2x107 A 4x107 A 4.3x107 A 3.7xl07 
B 3.3x107 B 3.2xl07 B 3.3x107 B 3.5x107 B 4.3x107 
Following total cell count for UT, ATRA, cis-RA, AJA (30 nM), AJA (3 ~M), CBD 
(30 nM), CBD (3 ~M), Hemp oil (30 nM), and Hemp oil (3 ~M), NBT assays were 

























HL-60 Treatment 11/24/14 
Figure 9: Results showing the differentiation between APL UT, ATRA, cis-RA, 
AJA (30 nM), AJA (3 ~-tM), CBD (30 nM), CBD (3 ~-tM), Hemp oil (30 nM), and 
Hemp oil (3 ~-tM) . 
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Discussion 
The use of cannabinoids as a possible source for medical treatments has 
received a lot of attention. Large amounts of research have been focusing on how 
these drugs help treat diseases such as cancer. One of these cannabinoids, AJA, has 
been studied extensively because it elicits no psychotropic effects when compared 
tetrahydrocannabinol (a compound from the marijuana plant that causes 
psychotropic effects). This research focused on using APL cells to help determine 
the possible receptor that AJA may be binding to when treating Ewing's sarcoma 
cells. 
APL cells (HL-60) underwent various forms of treatment throughout the 
experiment. Having the positive results from ATRA helped show the possible 
outcome if AJA did indeed bind to RAR-a. However, once the APL cells underwent 
treatment with AJA, there was little differentiation observed. Figure 10 shows the 
difference between normal WBC and abnormal WBC found in APL patients. The 
following figure is to show the desired affect of the drug, providing it did in fact bind 
to RAR-a. 
7() 
Figure 10: WBC observed in patients with APL (left) and WBC observed in 
healthy patients. The distinguishing difference between the two images in 
APL the nuclei of the cells are hard to distinguish (left) compared to those 
without APL (right). Therefore, if AJA did in fact bind to RAR-a, APL cells 
(left) would differentiate to normal WBC (right). 
From: American Society of Hematology Image Bank, Luhan Swart, Ann van 
Eyssen, Margie Shuttleworth (left) and Atlas Genetics Oncology (right) 
However, when APL cells underwent treatment with AJA, little or no 
differentiation was observed. Figure 11 shows the images taken from the lab with 
the various treatments (UT, ATRA (30 nM), and AJA (30 nM)). Even increasing the 
concentrations of AJA did not cause the APL cells to differentiate. Other sources of 
cannabinoids, such as CBD or Hemp oil, had the same results as AJA, little or no 
differentiation. Therefore, with these results, we believe that AJA does in fact bind 
to RARa in APL cells, however at a very low affinity. This suggests that AJA may be 
binding to more than one receptor. Further research is needed to test the other 




Figure 11: The top left image is APL cells UT, top right image is APL cells treated 
with 30 nM of ATRA, and the bottom left image is APL cells treated with 30 nM of 
AJA. There is clear evidence that AJA does induce some differentiation of APL cells, 
however a majority are still promyelocytes. 
?? 
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